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Abstract 17 
Background: In recent years the number of natural products used as pharmaceuticals, 18 
components of dietary supplements and cosmetics has increased tremendously requiring 19 
more extensive evaluation of their pharmacokinetic properties. 20 
Purpose: This study aims at combining in vitro and in silico methods to evaluate the 21 
gastrointestinal absorption (GIA) of natural flavonolignans from milk thistle (Silybum 22 
marianum (L.) Gaertn.) and their derivatives.  23 
Methods: A parallel artificial membrane permeability assay (PAMPA) was used to evaluate 24 
the transcellular permeability of the plant main components. A dataset of 269 compounds 25 
with measured PAMPA values and specialized software tools for calculating molecular 26 
descriptors were utilized to develop a quantitative structure-activity relationship (QSAR) 27 
model to predict PAMPA permeability. 28 
Results: The PAMPA permeabilities of 7 compounds constituting the main components of 29 
the milk thistle were measured and their GIA was evaluated. A freely-available and easy to 30 
use QSAR model predicting PAMPA permeability from calculated physico-chemical 31 
molecular descriptors was derived and validated on an external dataset of 783 compounds 32 
with known GIA. The predicted permeability values correlated well with obtained in vitro 33 
results. The QSAR model was further applied to predict the GIA of 31 experimentally 34 
untested flavonolignans. 35 
Conclusions: According to both in vitro and in silico results most flavonolignans are highly 36 
permeable in the gastrointestinal tract, which is a prerequisite for sufficient bioavailability 37 
and use as lead structures in drug development. The combined in vitro/in silico approach 38 
can be used for the preliminary evaluation of GIA and to guide further laboratory 39 
experiments on pharmacokinetic characterization of bioactive compounds, including natural 40 
products. 41 
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Introduction 52 
In recent years the number of natural products (NPs) used as pharmaceuticals, 53 
components of dietary supplements and cosmetics has increased tremendously. In 54 
particular, there is strong interest in research on flavonoids from plant sources due to their 55 
potential health benefits as reported from various epidemiological studies (Kumar and 56 
Pandey, 2013). Flavonoids have been shown to exhibit antioxidant (Chen et al., 2018), 57 
antidiabetic (Xiao and Hogger, 2014), hypocholesterolaemiac (Thilakarathna et al., 2012), 58 
antiplatelet (Khan et al., 2018), antibacterial (Xiao, 2015) and antiinflammatory effects 59 
(Chen et al., 2017) as well as the ability to modulate cell signaling and gene expression 60 
(Noll et al., 2009) related to infectious and cardiovascular diseases and different forms of 61 
cancer (Sak, 2014). Their low toxicity in general is considered a further major advantage of 62 
these compounds. However, most bioactivities of flavonoids have been reported from in 63 
vitro cell experiments, whereas the poor systemic bioavailability may limit their beneficial 64 
effects in vivo (Xiao and Högger, 2015; Xiao, 2018). Phase 2 metabolism is known to affect 65 
the bioavailability of flavonoids and, in general, metabolites of flavonoids show reduced 66 
bioactivity in comparison to parent compounds (Thilakarathna and Rupasinghe, 2013). 67 
Thus, bioavailability is an important pharmacokinetic property and should be considered as 68 
early as possible when NPs and their derivatives are considered for medicinal and drug 69 
discovery purposes. 70 
Among the flavonoids, flavonolignans are a relatively small subclass of compounds where 71 
the flavonoid part of the molecule is attached to a lignan (Biedermann et al., 2014). 72 
Flavonolignans were originally discovered in the seeds of milk thistle (Silybum marianum 73 
(L.) Gaertn.), a medicinal plant used from ancient times for the treatment of liver and 74 
gallbladder disorders of different etiologies. The herb active component, silymarin, is a 75 
mixture of flavonolignans, mainly silybin A and silybin B; other phenolic compounds such as 76 
isosilybin, dehydrosilybin, silychristin, silydianin and taxifolin are also found in its fruit and 77 
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seeds (Chambers et al., 2017; Pyszková et al., 2016). Silybin, as the major flavonolignan 78 
component of silymarin, is present as a quasi-equimolar mixture of the two diastereomers A 79 
and B (natural racemic silybin is noted below as silybin AB). Nowadays, silymarin is the 80 
best known for its antioxidant and chemoprotective effects on the liver (Křen and Walterová, 81 
2005) and is often prescribed or self-prescribed as a complementary hepatoprotective 82 
medicine (Testino et al., 2013). Furthermore, its use has been broadened to other organs in 83 
addition to the liver, e.g. in the treatment of pancreatic diseases and balancing glycaemia, 84 
lung and kidney diseases, in dermatological and cosmetic preparations. Other beneficial 85 
effects include hypocholesterolaemic, cardioprotective, neuroactive and neuroprotective 86 
properties (Křen and Walterová, 2005). Despite the frequent therapeutic use of silybin and 87 
its congeners, many of their pharmacokinetic properties affecting bioavailability, including 88 
gastrointestinal absorption (GIA), have not been well investigated. 89 
The aim of this study was to address this paucity of pharmacokinetic information by 90 
combining in vitro and in silico methods to evaluate the gastrointestinal absorption of 91 
natural flavonoids from milk thistle (Silybum marianum (L.) Gaertn.) and their derivatives 92 
with a particular focus on flavonolignans. The GIA of several flavonolignans was estimated 93 
using the parallel artificial membrane permeability assay (PAMPA). The PAMPA is an in 94 
vitro model of passive, transcellular permeation. It was introduced by Kansy et al. (1998) to 95 
predict oral absorption in a simple, reproducible and high-throughput manner. PAMPA is 96 
particularly advantageous in early stages of the drug discovery process. It is cost-effective 97 
and easy to automate, additionally it has proved to have good reproducibility and small 98 
variability. PAMPA permeability correlates well with GIA in vivo and it is now considered to 99 
be a good screening system to evaluate the permeability by the passive transcellular route 100 
(Ano et al., 2004; Verma et al., 2007). In combination with a high-throughput solubility 101 
assay it enables biopharmaceutical classification in the early drug discovery stage. Data 102 
from PAMPA have been subject to numerous quantitative structure-activity relationship 103 
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(QSAR) studies (Nakao et al., 2009; Leung et al., 2012). Here we report on an in silico 104 
evaluation of GIA for a broader set of silybin congeners using a QSAR model for the 105 
prediction of PAMPA permeability. The model was intentionally developed using descriptors 106 
calculated from open-source or free software tools or obtainable from free online resources 107 
(Cronin et al., 2012) and is freely available in the COSMOS KNIME WebPortal 108 
(http://knimewebportal.cosmostox.eu). It has also been included in the DataBase service on 109 
Alternative Methods of the European Union Reference Laboratory for alternatives to animal 110 
testing (https://ecvam-dbalm.jrc.ec.europa.eu). Whilst there is variability, the results of the 111 
analysis suggest that most of the flavonolignans studied may be considered as being highly 112 
permeable in the gastrointestinal tract, implying their potential good bioavailability and 113 
appropriateness for using as medicines and lead structures for drug development. 114 
 
Materials and methods 115 
Chemicals  116 
Seven compounds (Fig. 1), provided by the Laboratory of Biotransformation, Institute of 117 
Microbiology, Czech Academy of Sciences were investigated in vitro: silybin AB 118 
(Biedermann et al., 2014), isosilybin A (Gažák et al., 2013a), silychristin A, silydianin 119 
(Křenek et al., 2014),  2-3-dehydrosilybin AB (Gažák et al., 2013b), taxifolin and quercetin. 120 
This set of compounds was selected empirically to allow analysis of the structural features 121 
and physico-chemical properties that can influence permeability. Purity of the 122 
flavonolignans was above 96% (HPLC/PDA) and of taxifolin and quercetin above 99% 123 
(Sigma-Aldrich). 124 
In addition, the membrane permeability of another 31 silybin derivatives (Džubák et al., 125 
2006; Gažák et al., 2009, 2011; Kosina et al., 2002) were predicted in silico (see 126 
Supplementary Table 1 for their structures and SMILES codes). 127 
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PAMPA  128 
Double-SinkTM (DS) PAMPA (Avdeef, 2012) measurements were performed in the PAMPA 129 
Explorer Test System from Pion Inc. PAMPA “sandwiches” were formed from a StirwellTM 130 
96-well donor and acceptor plates with a polyvinylidene difluoride filter bottom, coated with 131 
a 20% (w/v) dodecane solution of lecithin (Pion Inc., PN 110669). The initial donor sample 132 
concentrations were ca. 20 μM. The acceptor compartment was filled with a surfactant-133 
containing buffer at pH 7.4 (Pion Inc., PN 110139); the donor compartment contained 134 
buffers at pH 5.0, 6.2, and 7.4 (Pion Inc., PN 110238). The sandwiches were incubated in a 135 
water vapor-saturated atmosphere at room temperature for 4 h in the Gut-BoxTM module 136 
with stirring to adjust the thickness of the aqueous boundary layer (ABL) to 60 μm.  137 
Sample concentrations in acceptor and donor wells were determined by UV 138 
spectrophotometry with an Epoch plate reader instrument (BioTek Inc). The effective 139 
permeability coefficient, Pe [cm.s-1], defined as the number of molecules (mol) diffusing 140 
through unit cross-section of the membrane (cm2) per unit of time (s) under a unit of 141 
concentration (mol·cm−3) gradient, was determined using the PAMPA Explorer software 142 
according to Avdeef (2012) (equations A7.28a,b). 143 
Three parallel measurements were made for each sample. Carbamazepine, ketoprofen and 144 
ranitidine were used as reference compounds; their measured PAMPA values reproduced 145 
those reported in the PAMPA Explorer documentation. 146 
Calculation of the pKa values  147 
The pKa values of the main components of silymarin were calculated in the ACD/Percepta 148 
software, v. 2016.1 (Advanced Chemistry Development, Inc., http://www.acdlabs.com) 149 
using the classical algorithm for pKa calculations under standard conditions (25°C and zero 150 
ionic strength, aqueous solution) for every ionizable group. Additionally, the pKa values for 151 
silybin B, quercetin and taxifolin were calculated using the empirical and quantum-chemical 152 
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pKa prediction modules in the Schrodinger software, release 2016-1 153 
(http://www.schrodinger.com). 154 
QSAR model development 155 
The data to construct the DS PAMPA Pe-predicting QSAR model were obtained from 156 
"Database of Double-Sink PAMPA log P0, log Pm6.5, and log Pm7.4" (Avdeef, 2012). The 157 
structural information was collected from the NCI/CADD Chemical Identifier Resolver 158 
service and from the NCBI PubChem project. Mixtures, compounds with zero permeability 159 
and compounds with permeability measured in the presence of a co-solvent were omitted, 160 
thus reducing the initial dataset from 292 to 269 compounds. After geometry optimization of 161 
the structures (MOPAC2012, http://openmopac.net), the total and polar water-accessible 162 
molecular surface areas were calculated in MOE, v. 2015.10 (MOE, 163 
http://www.chemcomp.com). Octanol-water distribution-related molecular descriptors (log D 164 
at pH 7.4) were calculated by ACD/Percepta or by the calculator plugins of ChemAxon 165 
Marvin v. 14.8.25 (http://chemaxon.com). Molecular size-related descriptors were 166 
calculated by the KNIME-integrated Chemistry Development Kit (CDK, v. 1.5.1) and Indigo 167 
(v. 1.1.4) nodes. The multiple linear regression models were derived and refined in the 168 
KNIME Analytics Platform v. 2.12.2 (http://www.knime.com). 169 
Results and discussion 170 
Measurement of PAMPA Permeability 171 
The compounds subjected to PAMPA permeability measurements were selected 172 
intentionally based on their plant distribution and structural relations: silybin AB 173 
(Biedermann et al., 2014), isosilybin A (Gažák et al., 2013a), silychristin A and silydianin 174 
(Křenek et al., 2014) are the main components of Silybum marianum; 2-3-dehydrosilybin 175 
AB (Gažák et al., 2013b) is an NP derivative but also occurs in silymarin as a minor 176 
component – up to 1–2% (Chambers et al., 2017); taxifolin and quercetin are structurally 177 
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identical to the flavonoid part of silybin and dehydrosilybin, respectively, and can be found 178 
in many fruits, vegetables, leaves, and grains. 179 
The logarithms of the effective membrane permeability values (log Pe) of the compounds 180 
studied are reported in Table 1. Good agreement is observed between the log Pe values of 181 
silybin and quercetin reported by Avdeef (2012) and those measured in the present study: ‒182 
5.08 vs. ‒5.25±0.05 for silybin, and ‒4.77 vs. ‒5.02±0.07 for quercetin. 183 
According to the high/low-to-moderate log Pe classification threshold of ‒6 (explained in 184 
section QSAR model for PAMPA prediction below) and the analysis of the measured log Pe 185 
values, the main active component of Silybum marianum, silybin, its 2,3-dehydro-derivative 186 
and isosilybin A can be considered to be highly permeable in the gastrointestinal tract. At 187 
pH 7.4 taxifolin and quercetin demonstrate a similar permeability profile. Silydianin and 188 
silychristin A, the second most abundant flavonolignans (after silybin) have lower log Pe 189 
values, suggesting lower absorption in the gastrointestinal tract. 190 
The results demonstrate clear dependence of the permeability of the compounds studied 191 
with pH. There is a difference of more than one log unit in log Pe at pH 7.4 between silybin 192 
and dehydrosilybin; however there is no significant variation at pH 5.0 and / or 6.2. 193 
Conversely, the difference in the permeability values between taxifolin and quercetin is 194 
higher at the lower pH (6.2 and 5.0). It may be assumed that dehydrogenation in the 195 
flavonoid core increases permeability of the flavonolignans at pH 7.4, but does not affect 196 
the permeability of the related flavonoids (quercetin and taxifolin), possibly related to the 197 
lignan part that is absent in taxifolin and quercetin. Regarding the influence of isomerism, 198 
comparison of the permeability values for silybin and isosilybin shows no significant 199 
difference with pH.  200 
Analysis of the pH dependence of permeability of individual compounds shows other 201 
significant variations. For silybin, isosilybin A, silychristin A and taxifolin there is a difference 202 
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of ca. one log unit between log Pe values measured at pH 6.2 and 7.4 (Table 1). However, 203 
such a difference was not observed for dehydrosilybin and quercetin. We assumed that 204 
these variations may be related to the ionization states of the compounds influencing the 205 
ratio between their neutral and ionized forms and thus their permeability. As an indicator of 206 
relative ionization, which would affect passive diffusion, the ACD/Percepta pKa values of 207 
the compounds were calculated. The lowest calculated acidic pKa values are presented in 208 
Fig. 1 and vary between 6.3 and 7.4, implying that at pH 7.4 the proportion of their ionized 209 
forms is higher compared to that at pH 6.2 and that should result in a lower permeability of 210 
the compounds. However, such a tendency has not been observed. Similar results have 211 
been recorded using more sophisticated pKa calculations by the specialized modules in 212 
Schrodinger software (data not shown). Three compounds with different profiles of log Pe 213 
dependence on pH have been studied: silybin B, quercetin and taxifolin. Again, the 214 
observed differences in their log Pe could not be referred to the differences in their pKa 215 
values. Thus, the calculated pKa values alone are unlikely to explain the effect of pKa on 216 
the pH-dependent log Pe of the studied compounds. 217 
QSAR model for PAMPA prediction 218 
In silico estimation of the GIA of the flavonoids was performed using a QSAR model for the 219 
prediction of PAMPA permeability. The model was developed using DS PAMPA data 220 
(Avdeef, 2012) obtained under experimental conditions equivalent to the PAMPA 221 
measurements performed in this study. The dataset of 269 compounds was characterized 222 
by a broad distribution of the Pe values. The sink conditions of DS PAMPA (lowering the 223 
active concentration of free permeant in the acceptor compartment) together with the ABL 224 
control (40-60 μm ABL achieved by in-well stirring) allowed for elimination of non-linearity of 225 
the Pe data across a broad range of lipophilicity. 226 
Molecular descriptors similar to those suggested by Kansy et al. (2001) ‒ the logarithm of 227 
the apparent octanol/water distribution coefficient (log D), and the ratio of polar to total 228 
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molecular surface area (PSA/TSA) ‒ were utilized in the QSAR. Log D values were 229 
calculated by ACD/Percepta or calculator plugins of ChemAxon Marvin. These log D 230 
estimates are readily available from http://www.chemspider.com (calculated by 231 
ACD/Percepta for compounds already included in the ChemSpider database) or from 232 
http://chemicalize.com (calculated by ChemAxon tools for any submitted compound).  233 
Substitution of the PSA/TSA ratio was considered to allow for the calculation of all 234 
descriptors with freely available software tools. As such PSA was substituted by TPSA 235 
(topological polar surface area (Ertl et al., 2000). To find an appropriate structural descriptor 236 
to substitute for TSA, polar and total surface areas and their ratio were calculated in MOE 237 
for all the compounds in the PAMPA dataset. Sixty-two descriptors related to molecular size 238 
were obtained and their relationships with TSA assessed (Table 2A), as were the 239 
relationships of TPSA/descriptor ratios to PSA/TSA (Table 2B). Following identification of 240 
the top-ranked TPSA/descriptor ratios, they were tested in the development of QSAR 241 
models. 242 
In order to increase the QSAR models' stability, high leverage compounds and the 243 
response outliers were filtered out. To evaluate the external predictivity of the models the 244 
datasets were split into training and test sets (4:1 stratified splitting). The goodness-of-fit (r2, 245 
SEE, F) and the internal leave-one-out cross-validation (LOO q2) statistics of the models 246 
were very close to those using PSA/TSA (Table 3), thus the substitution of any of the three 247 
top-ranked TPSA/descriptor ratios – TPSA/VABC (sum of atomic and bond contributions 248 
volume), TPSA/MW (molecular weight) and TPSA/AP (sum of atomic polarizations) for 249 
PSA/TSA – is well justified. The very close values of r2 and LOO q2 for all models 250 
demonstrate high model stability. The external predictivity coefficients are also in a narrow 251 
range (0.69-0.79) and similar to those using PSA/TSA (0.68 and 0.79 for ACD/Percepta 252 
and ChemAxon tools calculated log D-based models, respectively). Therefore, the use of 253 
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descriptors from freely available sources does not decrease the quality of the models and is 254 
justified for future use. 255 
Considering that MW is the most fundamental descriptor of the molecular size, and that the 256 
statistical parameters of the models using it were among the best, MW was selected to 257 
substitute for TSA. The two implementations of the model based on log D at pH 7.4 as 258 
estimated by the ACD/Percepta or ChemAxon tools are presented in equations 1 and 2, 259 
respectively: 260 
log Pe = ‒ 2.20(±0.21) + 0.49(±0.04)log D ‒ 10.14(±0.74)TPSA/MW (1) 261 
n = 251, r² = 0.75, SEE = 1.10, F = 371.3, 262 
LOO q² = 0.74, external validation q² = 0.79 (200/51) 263 
 
log Pe= ‒ 2.11(±0.22) + 0.47(±0.05)log D ‒ 10.71(±0.78)TPSA/MW (2) 264 
n = 248, r² = 0.74, SEE = 1.11, F = 345.1, 265 
LOO q² = 0.73, external validation q² = 0.77 (198/50) 266 
 
The ability of these models to predict GIA was assessed using an external dataset 267 
(accessible at http://biomed.bas.bg/qsarmm) of 783 compounds (1227 distinct values) with 268 
reported GIA collected from the literature, 167 of them (383 distinct GIA values) with DS 269 
PAMPA Pe in the training set of the model developed. The data collected did not distinguish 270 
low and medium GIA, due to the low percentage of compounds with low and medium GIA 271 
(Fig. 2A). However, a rapid decrease in the percentage of observations belonging to the 272 
highest GIA class (>80%) is evident for compounds with PAMPA log Pe lower than –6 (Fig. 273 
2B), which confirms the recommendation in Avdeef (2012) to use log Pe < –6 as an 274 
indication for possible low GIA. The model classified the remaining 616 compounds into 275 
high or medium-to-low GIA classes and the accuracy, sensitivity and specificity of the 276 
classification were calculated (Table 4). 277 
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In silico prediction of Pe for the flavonoids 278 
The results from the in silico prediction of PAMPA permeability for the compounds studied 279 
in vitro using the QSAR model are reported in Table 5. Fig. 3 represents their positions 280 
within the space defined by the physico-chemical parameters used for the development of 281 
the model for the compounds in the training set. The figure demonstrates that the 282 
compounds fall into the applicability domain of the model thus confirming the reliability of 283 
the predictions. 284 
The predicted log Pe values of the silybin congeners (silybin AB, 2,3-dehydrosilybin AB and 285 
isosilybin A, Table 5) correspond well to the measured PAMPA permeability at pH 7.4 286 
(Table 1). For these compounds, there is a difference of less than one log unit between the 287 
measured and calculated permeability values. For silychristin A and silydianin the predicted 288 
values are higher than those measured by more than 1.5 log units. Log D and TPSA/MW 289 
for these compounds are similar to those of silybin and 2,3-dehydrosilybin, suggesting the 290 
presence of specific structural features not accounted for by the model that result in higher 291 
than predicted membrane permeability.  292 
Fig. 4 illustrates the plot of experimental log Pe values vs. those calculated by the QSAR 293 
model for the flavonoids studied. Among the main components of milk thistle, silybin and its 294 
congeners show higher in vitro and in silico permeability. These findings are in agreement 295 
with previously reported in vivo data which indicate that silybin is absorbed rapidly in the 296 
gastrointestinal tract, although its low solubility and fast elimination remain major concerns 297 
with regard to bioavailability (Wu et al., 2009). 2,3-dehydrosilybin AB possesses the highest 298 
in vitro log Pe and close to that obtained by the QSAR model. The predicted permeabilities 299 
of taxifolin and quercetin differ from the experimental values by ca. one log unit and place 300 
these compounds close to the high/low permeability threshold.  301 
14 
 
Based on the good correspondence between the observed and calculated permeability of 302 
the silybin congeners (silybin AB, dehydrosilybin AB and isosilyibn A), the permeability of a 303 
further 31 silybin derivatives, with structural skeleton similar to those of the studied silybins 304 
and unknown permeability, was also predicted (data shown in Table 6 and Supplementary 305 
Table 1). As demonstrated in Fig. 5, high GIA can be expected for most of these 306 
compounds. Only four flavonolignans (silybinic acid, 2,3-dehydrosilybinic acid, silybin 23-O-307 
β-lactoside and silybin 23-O-β-maltoside) have log Pe values lower than ‒6. This could be 308 
attributed to the presence of highly polar carboxyl groups in the two acids and the bulky 309 
polar disaccharide moiety in the two glycosides. The majority of the compounds have log 310 
Pe values between ‒4 and ‒5, which classifies them as highly permeable. Additional 311 
experimental studies are necessary to confirm these predictions. 312 
 
Conclusions 313 
In the present study the PAMPA methodology has been applied to estimate the membrane 314 
permeability of all major components of Silybum marianum (L.) Gaertn. A QSAR model for 315 
PAMPA has been developed and combined with the in vitro results to predict the GIA of all 316 
major components of the milk thistle and their derivatives. The QSAR model uses 317 
descriptors calculated by open-source or free software tools or those obtainable from free 318 
online resources that makes it appropriate for a broader application. According to both in 319 
vitro and in silico methods most flavonolignans are highly permeable in the gastrointestinal 320 
tract, which is a good prerequisite for sufficient bioavailability. The estimated permeability of 321 
the studied flavonoids makes them appropriate lead structures for drug development 322 
purposes. The results confirm that the combined interdisciplinary approach based on in 323 
silico QSAR predictions and in vitro PAMPA measurements can be used for preliminary 324 
evaluation of GIA and can guide further laboratory experiments for characterization of 325 
bioactive compounds, including NPs. 326 
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Figures 462 
 
 463 
 464 
 465 
Fig. 1. Chemical structures of the flavonoids investigated in vitro and their calculated lowest acidic 466 
pKa values shown next to the corresponding hydroxyl group. 467 
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 469 
 470 
 471 
 472 
Fig. 2. Correspondence between log Pe and GIA (%) for 167 compounds present in both PAMPA 473 
Pe and GIA datasets: A – mean GIA values vs. PAMPA log Pe; size of the circles corresponds to 474 
the number of averaged GIA values for the compound. B – distribution of GIA classes among 475 
PAMPA Pe classes (numbers on top of the columns correspond to the number of distinct GIA 476 
values in each PAMPA Pe class). 477 
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 479 
 480 
Fig. 3. 3-D plots of experimental log Pe vs. calculated structural descriptors TPSA/MW (A) and log 481 
D at pH 7.4 (B) obtained by the ACD/Percepta model (equation 1) as the x-axis respectively for the 482 
training set of compounds (◦) and the predicted flavonoids (•). The parameters’ intervals are: ‒483 
9÷0.78 for log Pe; 0.011÷0.695 for TPSA/MW and ‒3.16÷5.51 for log D (pH 7.4). 484 
 
  485 
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 486 
 487 
 488 
Fig. 4. Plot of experimental vs. calculated log Pe values for the flavonoids studied: ○ – compounds 489 
used to derive the PAMPA QSAR model; ● – compounds studied: silybin AB (1), 2,3‒dehydrosilybin 490 
AB (2), isosilybin A (3); silychristin A (4), silydianin (5), taxifolin (6), quercetin (7); the dashed line 491 
represents the border between low and high permeability. 492 
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 495 
 496 
 497 
Fig. 5. Distribution of the flavonolignans according to their predicted log Pe. 498 
  499 
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Tables 500 
 
Table 1. Effective membrane permeability log Pe ± SD of the compounds studied. The SD values 501 
have been calculated based on 3 parallel experiments. 502 
 pH 5.0 6.2 7.4 503 
Compound 504 
Silybin AB  ‒4.11 ± 0.03 ‒4.14 ± 0.03 ‒5.25 ± 0.05 505 
2,3-Dehydrosilybin AB  ‒4.11 ± 0.06 ‒4.17 ± 0.03 ‒4.06 ± 0.03 506 
Isosilybin A  ‒4.32 ± 0.09 ‒4.31 ±0.06  ‒5.19 ± 0.02 507 
Silychristin A  ‒6.14 ± 0.08 ‒6.09 ± 0.05 ‒6.75 ± 0.11 508 
Silydianin  ‒5.76 ± 0.05 ‒5.79 ± 0.04 ‒6.64 ± 0.09 509 
Taxifolin  ‒5.95 ± 0.10 ‒5.93 ± 0.02 ‒5.23 ± 0.01 510 
Quercetin  ‒5.14 ± 0.42 ‒5.10 ± 0.17 ‒5.02 ± 0.07 511 
 512 
 513 
 
  514 
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Table 2. The CDK and Indigo calculated molecular descriptors and TPSA/descriptor ratios with the 515 
highest correlation to TSA (A) and to PSA/TSA (B). 516 
 
A  B 517 
Descriptors r Ratios r 518 
 519 
TSA 1.000 PSA/TSA 1.000 520 
Atomic polarizabilities 0.959 TPSA/VABC volume descriptor 0.881 521 
Number of heavy atoms 0.957 TPSA/Molecular weight 0.880 522 
VABC volume descriptor 0.954 TPSA/Atomic polarizabilities 0.878 523 
Number of bonds 0.951 TPSA/Number of heavy atoms 0.876 524 
Number of carbons 0.950 TPSA/Total number of atoms 0.873 525 
Molecular weight 0.946 TPSA/Bond polarizabilities 0.848 526 
Total number of atoms 0.941 TPSA/Number of bonds 0.842 527 
Zagreb index 0.923 TPSA/Zagreb index 0.801 528 
Vertex adjacency information 0.917 TPSA/Number of carbons 0.740 529 
magnitude 530 
Bond polarizabilities 0.913 TPSA/Vertex adjacency information 0.686 531 
  magnitude 532 
r – correlation coefficient, TSA – total surface area, PSA – polar surface area, TPSA – topological 533 
polar surface area, VABC – sum of atomic and bond contributions volume. 534 
 535 
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Table 3. Statistical parameters of a set of tested DS-PAMPA Pe models based on two differently 537 
calculated log D estimates, on PSA/TSA, and on three different substitutes for the PSA/TSA ratio. 538 
 
A 539 
 surface N r2 SEE F LOO q2 540 
log D descriptors 541 
 PSA/TSA 259 0.69 1.20 286 0.68 542 
ACD/Percepta- TPSA/VABC 254 0.74 1.11 354 0.73 543 
calculated TPSA/MW 251 0.75 1.10 371 0.74 544 
 TPSA/AP 253 0.74 1.10 350 0.73 545 
 546 
B 547 
 surface N r2 SEE F LOO q2 548 
log D descriptors 549 
 PSA/TSA 245 0.75 1.08 370 0.75 550 
ChemAxon tools- TPSA/VABC 245 0.74 1.09 348 0.74 551 
calculated TPSA/MW 248 0.74 1.11 345 0.73 552 
 TPSA/AP 245 0.74 1.09 351 0.74 553 
N – number of compounds in the model set (starting number of compounds was 269), r2 – multiple 554 
correlation coefficient, SEE – standard error of estimate, F – F-ratio, LOO q2 – leave-one-out cross-555 
validation correlation coefficient, VABC – sum of atomic and bond contributions volume, MW – 556 
molecular weight, AP – atomic polarizabilities. 557 
 558 
 
 
  559 
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Table 4. Statistical parameters for the classification power of the PAMPA Pe, predicted by TPSA/MW-560 
based models, with respect to GIA. 561 
 
 
Model accuracy sensitivity specificity % outliers 562 
implementation 563 
ACD/Percepta- 76.1 83.9 58.3 11.6 564 
calculated log D 565 
ChemAxon tools- 77.1 84.4 60.0 14.6 566 
calculated log D 567 
 568 
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Table 5. Calculated molecular descriptors and log Pe values predicted by the QSAR model for the 570 
flavonoids studied. 571 
Compound log D at pH 7.4 TPSA/MW Predicted log Pe 572 
Silybin AB 1.77 0.322 ‒4.60 573 
2,3-Dehydrosilybin AB 1.03 0.331 ‒5.06 574 
Isosilybin A 1.82 0.322 ‒4.57 575 
Silychristin A 1.70 0.345 ‒4.86 576 
Silydianin 1.03 0.338 ‒5.12 577 
Taxifolin 1.15 0.419 ‒5.89 578 
Quercetin 0.59 0.435 ‒6.32 579 
 580 
 581 
  582 
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Table 6. Calculated values of the molecular descriptors and log Pe values predicted by the QSAR 583 
model of 31 silybin congeners. 584 
Name log D TPSA/MW Predicted log Pe 585 
 at pH 7.4  at pH 7.4 586 
7-O-Benzylsilybin a 3.89 0.252 ‒2.85 587 
5,7,20-tri-O-Methylsilybin a 2.92 0.233 ‒3.13 588 
7-O-Benzoylsilybin a 3.65 0.275 ‒3.20 589 
5,7,20-tri-O-Methyl-2,3-dehydrosilybin a 2.71 0.241 ‒3.32 590 
23-O-Pivaloylsilybin a 3.40 0.285 ‒3.42 591 
7-O-Benzyl-2,3-dehydrosilybin a 2.87 0.260 ‒3.43 592 
3,7,20-tri-O-Methyl-2,3-dehydrosilybin a 2.28 0.241 ‒3.53 593 
7,20-di-O-Methylsilybin a 2.68 0.261 ‒3.54 594 
19-O-Demethyl-19-O-benzyl-2,3-dehydrosilybin a 2.45 0.286 ‒3.90 595 
7,20-di-O-Methyl-2,3-dehydrosilybin a 1.93 0.270 ‒3.99 596 
3-O-Methyl-silybin b 2.35 0.291 ‒4.00 597 
7-O-Methylsilybin a 2.26 0.291 ‒4.04 598 
20-O-Methylsilybin a 2.21 0.291 ‒4.07 599 
3,7-di-O-Methyl-2,3-dehydrosilybin a 1.73 0.270 ‒4.09 600 
3,20-di-O-Methyl-2,3-dehydrosilybin a 1.59 0.270 ‒4.16 601 
23-O-Galloylsilybin c 2.85 0.350 ‒4.35 602 
23-O-Methyl-2,3-dehydrosilybin b 1.70 0.300 ‒4.41 603 
7-O-Methyl-2,3-dehydrosilybin a 1.62 0.300 ‒4.45 604 
3-O-Galloylsilybin c 2.60 0.350 ‒4.48 605 
20-O-Methyl-2,3-dehydrosilybin a 1.52 0.300 ‒4.49 606 
20-O-Galloylsilybin c 2.55 0.350 ‒4.50 607 
5-O-Methyl-dehydrosilybin b 1.46 0.300 ‒4.52 608 
3-O-Methyl-2,3-dehydrosilybin a 1.36 0.300 ‒4.57 609 
7-O-Galloylsilybin c 1.86 0.350 ‒4.84 610 
19-O-Demethyl-2,3-dehydrosilybin a 0.88 0.365 ‒5.47 611 
Silybin 23-O-β-galactoside d ‒0.12 0.364 ‒5.95 612 
Silybin 23-O-β-glucoside d ‒0.12 0.364 ‒5.95 613 
Silybinic acid a ‒1.75 0.347 ‒6.58 614 
Silybin 23-O-β-lactoside d ‒1.00 0.389 ‒6.63 615 
Silybin 23-O-β-maltoside d ‒1.00 0.389 ‒6.63 616 
2,3-Dehydrosilybinic acid a ‒2.28 0.356 ‒6.93 617 
Structures taken from: a Džubák et al. (2006), b Gažák et al. (2009), c Gažák et al. (2011), d Kosina 618 
et al. (2002). 619 
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